Scientific Programme


Wednesday 28 May 2008

14.00 – 16.00
Opening Ceremony / Plenary Session 1

Challenges in HIV Infection

Chairs: Alain Lafeuillade, Toulon, France; Stefano Vella, Rome, Italy

  • Managing HIV Drug Interactions
    David Back, Liverpool, UK
  • The Challenges of HIV Reservoirs & Persistence
    Tae-Wook Chun,     Bethesda, USA
  • Anti-HIV Vaccine Development
    Robert Gallo, Baltimore, USA

 

16.30 - 18:00
Satellite Symposium
Tibotec, a division of Janssen-Cilag

Combating and Preventing Antiviral Drug Resistance: From Drug Discovery to Clinical Evidences

  • Drug Discovery and Investigational Compounds in Development at Tibotec
    Brian Woodfall    , Mechelen, Belgium
  • A Next-Generation NNRTI for Managing Treatment-Experienced HIV-1-Infected Patients
    Giovanni Di Perri, Turin, Italy
  • Darunavir: Virological Features
    Vincent Calvez, Paris, France


Thursday 29 May 2008

8.00 - 9.00
Meet The Experts 1
Including Resistance Testing in Clinical Practise

Mark Wainberg, Montréal, Canada
Anna Maria Geretti, London, UK

Supported by an Unrestricted Educational Grant from MSD-Chibret

8.00 - 9.00
Meet The Experts 2
Managing HIV HCV Coinfection in Practise

Jürgen Rockstroh, Bonn, Germany
José M. Miró, Barcelona, Spain
 

 

9.15 – 10.45
Plenary Session 2

HAART From Today to Tomorrow

Chairs: Alain Lafeuillade, Toulon, France;Caroline Solas, Marseille, France

  • When May We Use HIV-1 Integrase Inhibitors in Our Strategies?
    David Cooper    , Sydney, Australia
  • New Antiretroviral Drugs in the Pipeline
    Roy Gulick    , New York, USA
  • HAART Tomorrow: considering difficulties ahead
     Mark Wainberg, Montréal, Canada

 

11.15 – 12.15
Panel 1
Which is the Best Treatment for Antiretroviral Naive Patients?

Stefano Vella, Rome, Italy
José Gatell, Barcelona, Spain
Richard Haubrich, San Diego, USA

11.15 - 12.15
Panel 2
Renal Dysfunction and Antiretroviral Therapy

Christoph Fux, Bern, Switzerland
Bruce Hendry, London, UK
Pablo Labarga, Madrid, Spain
Corinne Bagnis, Paris, France

12.30 – 13.30
Lunch Symposium
Schering-Plough  

Vicriviroc: A Next Generation CCR5 Antagonist for HIV Treatment

Lisa M. Dunkle, Kenilworth, USA                  


       

 

12.30 – 13.30
Lunch Symposium
GlaxoSmithKline

First Line Therapy in 2008

Alain Lafeuillade, Toulon, France (Chair)
Isabelle Poizot-Martin, Marseille, France
Jean-Claude Tardy, Lyon, France

This symposium will be held in French with simultaneous translation into English

14.00 – 15.30
Satellite Symposium
Gilead

HIV Infection Complications

  • Which role for HIV infection in complications? Cécile Goujard, Le Kremlin Bicêtre, France
  • Which role for HAART complications and how to manage them? Thierry Prazuck, Orléans, France
  • Focus on cardiovascular risk and lipid disorders; Stéphane de Wit, Brussels, Belgium

16.00 – 17.00
Point / Counterpoint 1
A Pivotal Role for HIV Entry Inhibitors?

Animator: Richard Haubrich, San Diego, USA
Pros: Eva Poveda, Madrid, Spain
Cons: Stéphane de Wit, Brussels, Belgium

 16.00 - 17.00
Point / Counterpoint 2
A Future for Immune-based Therapy in HIV?

Pros: Guido Poli, Milan, Italy
Cons: Jade Ghosn, Paris, France
17.15 – 18.45
Parallel Session 1

Chairs:
Patricia Enel, Marseille, France
Alain Lafeuillade,Toulon, France

 17.15 - 18.45
Parallel Session 2

 Chairs:
Alain Rieu, Toulon, France
Gilles Hittinger, Toulon France


Friday 30 May 2008

8.00 – 9.00
Meet The Experts 3
Including TDM in Clinical Practice

Rodolphe Garraffo, Nice, France
Giovanni Di Perri, Turin, Italy




8.00 - 9.00
Meet The Experts 4
Practical Management of Metabolic Complications in HIV+ Patients

William Powderly, Dublin, Ireland

Supported by an Unrestricted Educational Grant from Boehringer Ingelheim

9.15 – 10.45
Plenary Session 3

Hepatitis Viruses & Coinfection

Chairs: Pierre Pellegrino, London, UK; Antoine Chéret, Toulon, France

  • New Paradigms in the Treatment of Hepatitis C in HIV
    Vicente Soriano, Madrid, Spain
  • Acute HCV Infection
    Mark Nelson, London, UK
  • Treatment of HBV infection: How Do the New Agents Fit?
    Yves Benhamou, Paris, France

 

11.15 – 12.15
Panel 3
Pre-exposure Prophylaxis for HIV Infection?

Eric De Clercq, Leuven, Belgium
Lynn A. Paxton, Atlanta, USA
                  

11.15 - 12.15
Panel 4
Liver Toxicity of Antiretroviral Drugs

Pablo Barreiro, Madrid, Spain
Stanislas Pol, Paris, France
Vicente Soriano, Madrid, Spain

Supported by an Unrestricted Educational Grant from Boehringer Ingelheim

12.30 – 13.30
Poster Discussion

12.30 - 13.30
Lunch Symposium
Bristol-Myers Squibb

What is the Definition of an Active Antiretroviral in 2008?

Chairs:
Alain Lafeuillade, Toulon, France
Jacques Izopet Toulouse, France

  • First part:When HIV Infection is Diagnosed at a Late Stage
    Graeme Moyle, London, UK
  • Second part: Which Role for Virology in Early-Treatment Lines?
    Jonathan Shapiro,     Tel-Hashomer,Israel
  • Q&A

14.30 – 15.30
Parallel Session 3

Chairs:
Christophe Renou, Hyères, France
Bruno Lacarelle, Marseille, France

 14.30 - 15.30
Parallel Session 4

 Chairs:
Eric Jullian, Toulon, France
Leondios Kostrikis, Nicosia, Cyprus

15.45 – 17.00
Rapporteur Session / Closing Ceremony

Chairs:
Alain Lafeuillade, Toulon, France
Jean-Claude Tardy, Lyon, France

Rapporteurs:
Rodolphe Garraffo,Nice, France
Marie-Lise Gougeon, Paris, France
Christine Rouzioux, Paris, France
Vincent Soriano, Madrid, Spain
Hans-Jürgen Stellbrink, Hamburg, Germany